These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24836206)

  • 1. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now?
    O'Sullivan BP
    Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206
    [No Abstract]   [Full Text] [Related]  

  • 2. Ignoring the nonsense: a phase II trial in cystic fibrosis.
    Hyde SC; Gill DR
    Lancet; 2008 Aug; 372(9640):691-2. PubMed ID: 18722009
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
    Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M
    Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
    Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.
    Wilschanski M; Miller LL; Shoseyov D; Blau H; Rivlin J; Aviram M; Cohen M; Armoni S; Yaakov Y; Pugatsch T; Cohen-Cymberknoh M; Miller NL; Reha A; Northcutt VJ; Hirawat S; Donnelly K; Elfring GL; Ajayi T; Kerem E
    Eur Respir J; 2011 Jul; 38(1):59-69. PubMed ID: 21233271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of the basic defect in cystic fibrosis.
    Roomans GM
    Cell Biol Int; 2014 Nov; 38(11):1244-6. PubMed ID: 24809326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam A; Jahnke N; Remmington T; Southern KW
    Paediatr Respir Rev; 2017 Sep; 24():32-34. PubMed ID: 28566196
    [No Abstract]   [Full Text] [Related]  

  • 11. Ataluren in cystic fibrosis: development, clinical studies and where are we now?
    Zainal Abidin N; Haq IJ; Gardner AI; Brodlie M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1363-1371. PubMed ID: 28730885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug developers aim to treat cystic fibrosis through disease modification.
    Thompson CA
    Am J Health Syst Pharm; 2008 Dec; 65(24):2310-2. PubMed ID: 19052266
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging drug treatments for cystic fibrosis.
    Zeitlin PL
    Expert Opin Emerg Drugs; 2007 May; 12(2):329-36. PubMed ID: 17604505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in cystic fibrosis 2008.
    Ratjen F
    Am J Respir Crit Care Med; 2009 Mar; 179(6):445-8. PubMed ID: 19264980
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
    Amaral MD
    J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.